L. Andreoletti, T. Blanchon, F. Carrat, X. Duval, A. Guimfack et al., Clinical study manager: Charlois-Ou C. Other members: Bouscambert Invited members (informed of study design but did not participate in any decision-making study discussions; supplied drugs and placebos), Steering committee: Leport C Gysembergh-Houal A (AP-HP)

G. Chêne, C. Hannoun, D. Vittecoq, S. Boucherit, Q. Dornic et al., Monitoring and statistical analysis Studypharm clinical research organisations Clinical investigators, Independent data-monitoring committee

R. 1. Burch, J. Corbett, M. Stock, C. Nicholson, K. Elliot et al., Prescription of anti-influenza drugs for healthy adults: a systematic review and meta-analysis, The Lancet Infectious Diseases, vol.9, issue.9, pp.537-545, 2009.
DOI : 10.1016/S1473-3099(09)70199-9

F. Hayden, A. Osterhaus, J. Treanor, D. Fleming, and F. Aoki, Efficacy and Safety of the Neuraminidase Inhibitor Zanamivir in the Treatment of Influenzavirus Infections, New England Journal of Medicine, vol.337, issue.13, pp.874-880, 1997.
DOI : 10.1056/NEJM199709253371302

K. Nicholson, F. Aoki, A. Osterhaus, S. Trottier, and O. Carewicz, Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial, Neuraminidase Inhibitor Flu Treatment Investigator Group, pp.1845-1850, 2000.
DOI : 10.1016/S0140-6736(00)02288-1

J. Treanor, F. Hayden, P. Vrooman, R. Barbarash, and R. Bettis, Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza, JAMA, vol.283, issue.8, pp.1016-1024, 2000.
DOI : 10.1001/jama.283.8.1016

T. Jefferson, M. Jones, and P. Doshi, Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis, BMJ, vol.339, issue.dec07 2, p.5106, 2009.
DOI : 10.1136/bmj.b5106

T. Puhakka, H. Lehti, R. Vainionpaa, V. Jormanainen, and M. Pulkkinen, Zanamivir: a Significant Reduction in Viral Load During Treatment in Military Conscripts with Influenza, Scandinavian Journal of Infectious Diseases, vol.35, issue.1, pp.52-58, 2003.
DOI : 10.1080/0036554021000026981

G. Poland, R. Jacobson, and I. Ovsyannikova, Influenza Virus Resistance to Antiviral Agents: A Plea for Rational Use, Clinical Infectious Diseases, vol.48, issue.9, pp.1254-1256, 2009.
DOI : 10.1086/598989

J. Wu, G. Leung, M. Lipsitch, B. Cooper, and S. Riley, Hedging against Antiviral Resistance during the Next Influenza Pandemic Using Small Stockpiles of an Alternative Chemotherapy, PLoS Medicine, vol.312, issue.5, 2009.
DOI : 10.1371/journal.pmed.1000085.s005

T. Sheu, V. Deyde, M. Okomo-adhiambo, R. Garten, and X. Xu, Surveillance for Neuraminidase Inhibitor Resistance among Human Influenza A and B Viruses Circulating Worldwide from 2004 to 2008, Antimicrobial Agents and Chemotherapy, vol.52, issue.9, pp.3284-3292, 2004.
DOI : 10.1128/AAC.00555-08

F. Dawood, S. Jain, L. Finelli, M. Shaw, and S. Lindstrom, Emergence of a novel swine-origin influenza A (H1N1) virus in humans, N Engl J Med, vol.360, pp.2605-2615, 2009.

S. Wong, J. Chan, K. Lee, E. Lo, and D. Tsang, Development of a quantitative assay for SARS coronavirus and correlation of GAPDH mRNA with SARS coronavirus in clinical specimens, Journal of Clinical Pathology, vol.58, issue.3, pp.276-280, 2005.
DOI : 10.1136/jcp.2004.016592

M. Duchamp, J. Casalegno, Y. Gillet, E. Frobert, and E. Bernard, Pandemic A(H1N1)2009 influenza virus detection by real time RT-PCR : is viral quantification useful?, Clinical Microbiology and Infection, vol.16, issue.4, pp.317-321, 2010.
DOI : 10.1111/j.1469-0691.2010.03169.x

F. Hayden, J. Treanor, R. Fritz, M. Lobo, and R. Betts, Use of the Oral Neuraminidase Inhibitor Oseltamivir in Experimental Human Influenza, JAMA, vol.282, issue.13, pp.1240-1246, 1999.
DOI : 10.1001/jama.282.13.1240

L. Gubareva, L. Kaiser, and F. Hayden, Influenza virus neuraminidase inhibitors, The Lancet, vol.355, issue.9206, pp.827-835, 2000.
DOI : 10.1016/S0140-6736(99)11433-8

J. Nguyen, J. Hoopes, M. Le, D. Smee, and A. Patick, Triple Combination of Amantadine, Ribavirin, and Oseltamivir Is Highly Active and Synergistic against Drug Resistant Influenza Virus Strains In Vitro, PLoS ONE, vol.348, issue.2, 2010.
DOI : 10.1371/journal.pone.0009332.s006

R. Russell, L. Haire, D. Stevens, P. Collins, and Y. Lin, The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design, Nature, vol.232, issue.7107, pp.45-49, 2006.
DOI : 10.1107/S0108767390010224

F. Aoki, G. Boivin, and N. Roberts, Influenza virus susceptibility and resistance to oseltamivir, Antivir Ther, vol.12, pp.603-616, 2007.

L. Gubareva, L. Kaiser, M. Matrosovich, Y. Soo-hoo, and F. Hayden, Selection of Influenza Virus Mutants in Experimentally Infected Volunteers Treated with Oseltamivir, The Journal of Infectious Diseases, vol.183, issue.4, pp.523-531, 2001.
DOI : 10.1086/318537

I. Stephenson, J. Democratis, A. Lackenby, T. Mcnally, and J. Smith, Neuraminidase Inhibitor Resistance after Oseltamivir Treatment of Acute Influenza A and B in Children, Clinical Infectious Diseases, vol.48, issue.4, pp.389-396, 2009.
DOI : 10.1086/596311